Dapagliflozin Enhances Fat Oxidation and Ketone Production in Patients With Type 2 Diabetes
暂无分享,去创建一个
R. DeFronzo | M. Abdul-Ghani | G. Daniele | C. Solis-Herrera | L. Norton | D. Tripathy | R. Eldor | Aurora Merovci | J. Xiong | Carolina Solis-Herrera | Giuseppe Daniele
[1] André Rodrigues,et al. Mellitus , 2018, Proceedings of the 17th International Conference on Mobile and Ubiquitous Multimedia.
[2] S. Mudaliar,et al. Can a Shift in Fuel Energetics Explain the Beneficial Cardiorenal Outcomes in the EMPA-REG OUTCOME Study? A Unifying Hypothesis , 2016, Diabetes Care.
[3] E. Ferrannini,et al. CV Protection in the EMPA-REG OUTCOME Trial: A “Thrifty Substrate” Hypothesis , 2016, Diabetes Care.
[4] R. DeFronzo,et al. SGLT2 Inhibitors and Cardiovascular Risk: Lessons Learned From the EMPA-REG OUTCOME Study , 2016, Diabetes Care.
[5] K. Margulies,et al. Evidence for Intramyocardial Disruption of Lipid Metabolism and Increased Myocardial Ketone Utilization in Advanced Human Heart Failure , 2016, Circulation.
[6] T. Pieber,et al. Shift to Fatty Substrate Utilization in Response to Sodium–Glucose Cotransporter 2 Inhibition in Subjects Without Diabetes and Patients With Type 2 Diabetes , 2016, Diabetes.
[7] B. Zinman,et al. Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes. , 2015, The New England journal of medicine.
[8] Simeon I. Taylor,et al. SGLT2 Inhibitors May Predispose to Ketoacidosis. , 2015, The Journal of clinical endocrinology and metabolism.
[9] I. Hirsch,et al. Euglycemic Diabetic Ketoacidosis: A Potential Complication of Treatment With Sodium–Glucose Cotransporter 2 Inhibition , 2015, Diabetes Care.
[10] A. Kitabchi,et al. Diabetic ketoacidosis and hyperosmolar state , 2015 .
[11] R. DeFronzo,et al. Dapagliflozin lowers plasma glucose concentration and improves β-cell function. , 2015, The Journal of clinical endocrinology and metabolism.
[12] R. DeFronzo,et al. Chapter 35 – Regulation of Intermediary Metabolism During Fasting and Feeding , 2015 .
[13] R. DeFronzo,et al. Chronic Reduction of Plasma Free Fatty Acid Improves Mitochondrial Function and Whole-Body Insulin Sensitivity in Obese and Type 2 Diabetic Individuals , 2014, Diabetes.
[14] R. DeFronzo,et al. Dapagliflozin improves muscle insulin sensitivity but enhances endogenous glucose production. , 2014, The Journal of clinical investigation.
[15] T. Heise,et al. Metabolic response to sodium-glucose cotransporter 2 inhibition in type 2 diabetic patients. , 2014, The Journal of clinical investigation.
[16] R. DeFronzo,et al. Dapagliflozin for the treatment of type 2 diabetes , 2013, Expert opinion on pharmacotherapy.
[17] M. Roden,et al. The role of mitochondria in insulin resistance and type 2 diabetes mellitus , 2012, Nature Reviews Endocrinology.
[18] R. DeFronzo,et al. Role of sodium-glucose cotransporter 2 (SGLT 2) inhibitors in the treatment of type 2 diabetes. , 2011, Endocrine reviews.
[19] D. Loo,et al. Biology of human sodium glucose transporters. , 2011, Physiological reviews.
[20] Ralph A. DeFronzo,et al. From the Triumvirate to the Ominous Octet: A New Paradigm for the Treatment of Type 2 Diabetes Mellitus , 2009, Diabetes.
[21] L. Heilbronn,et al. Is mitochondrial dysfunction a cause of insulin resistance? , 2008, Trends in Endocrinology & Metabolism.
[22] R. DeFronzo,et al. Deleterious action of FA metabolites on ATP synthesis: possible link between lipotoxicity, mitochondrial dysfunction, and insulin resistance. , 2008, American journal of physiology. Endocrinology and metabolism.
[23] K. Petersen,et al. Molecular Mechanisms of Insulin Resistance in Humans and Their Potential Links With Mitochondrial Dysfunction , 2006, Diabetes.
[24] William C Stanley,et al. Myocardial substrate metabolism in the normal and failing heart. , 2005, Physiological reviews.
[25] C Cobelli,et al. Roles of glucose transport and glucose phosphorylation in muscle insulin resistance of NIDDM. , 1996, Diabetes.
[26] D. McClain,et al. Regulation of Glycogen Synthase by Glucose, Glucosamine, and Glutamine:Fructose-6-Phosphate Amidotransferase , 1995, Diabetes.
[27] R. DeFronzo,et al. Indirect calorimetry: methodological and interpretative problems. , 1990, The American journal of physiology.
[28] R G Shulman,et al. Quantitation of muscle glycogen synthesis in normal subjects and subjects with non-insulin-dependent diabetes by 13C nuclear magnetic resonance spectroscopy. , 1990, The New England journal of medicine.
[29] R. DeFronzo,et al. Glucose clamp technique: a method for quantifying insulin secretion and resistance. , 1979, The American journal of physiology.
[30] J. McGarry,et al. Hormonal control of ketogenesis. Rapid activation of hepatic ketogenic capacity in fed rats by anti-insulin serum and glucagon. , 1975, The Journal of clinical investigation.